RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Paediatric investigation plan (European Union), Promising Innovative Medicine (United Kingdom), Priority Review (United States)

Structure/Sequence

Sequence Code 18457995

Source: *****

Clinical Trials associated with Efgartigimod Alfa

NCT06831058

/ Not yet recruitingPhase 2IIT

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Immune-mediated Thrombotic thrombocytopenic purpura (iTTP) is a rare, autoimmune disorder characterized by life-threatening episodes of thrombocytopenia, microangiopathic hemolytic anemia and organ damage. Patients have an unpredictable course punctuated by relapses associated with autoantibody-mediated (primarily IgG) depletion of ADAMTS13, a key regulator of coagulation. ADAMTS13 deficiency during remission has been associated with increased risk of relapse, but also, and potentially more devastating, ischemic stroke.
Until recently, it was presumed that rituximab (a monoclonal antibody targeting B cells) improved relapse-free survival in most patients, but this was based on findings from very small studies. Given concern about stroke and relapse risk, preventive immunosuppression with rituximab has also recently come into practice for patients with falling ADAMTS13 activity (ADAMTS13-relapse). It is expected that following efgartigimod therapy, there will be a rise in ADAMTS13 activity to the normal range that will be sustained during the treatment period. Following withdrawal of therapy, it is expected that most participants will experience a fall in ADAMTS13 activity, demonstrating the safety and efficacy in efgartigimod to reliably but temporarily reduce pathogenic antibodies. This would demonstrate the potential efficacy for efgartigimod as a maintenance therapy to safely prevent relapse of iTTP to be further explored in a larger efficacy study.

Start Date01 May 2025

Sponsor / Collaborator

University of Minnesota

NCT06885762

/ Not yet recruitingPhase 2/3IIT

Safety and Efficacy of Efgartigimod in Guillain-Barré Syndrome

The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are:
Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod?
Participants will:
On day 1 and day 5 of the treatment period, drug A was administered intravenously.
Keep a diary of their symptoms

Start Date13 Apr 2025

Sponsor / Collaborator

Xinqiao Hospital

NCT06909214

/ Not yet recruitingPhase 4

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis

The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.

Start Date01 Apr 2025

Sponsor / Collaborator

argenx SE

100 Clinical Results associated with Efgartigimod Alfa

100 Translational Medicine associated with Efgartigimod Alfa

100 Patents (Medical) associated with Efgartigimod Alfa

166

Literatures (Medical) associated with Efgartigimod Alfa

31 Dec 2025·Human Vaccines & Immunotherapeutics

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models

Article

Author: Vanhoenacker, Peter ; Baumeister, Judith ; Wouters, Heidi ; Schotsaert, Michael ; Laghlali, Gabriel ; Ulrichts, Peter ; Chang, Lauren A ; Singh, Gagandeep ; Binazon, Ornella ; Warang, Prajakta ; Elhemdaoui, Nadia ; Augustynková, Kateřina ; Moshir, Mahan ; Steeland, Sophie ; Notebaert, Margo

Antagonism of the neonatal Fc receptor through an engineered antibody Fc fragment, such as efgartigimod, results in a decrease in immunoglobulin G levels. This approach is being evaluated as a therapeutic strategy for the treatment of IgG-mediated autoimmune diseases. Our goal was to evaluate the impact of mFc-ABDEG, a mouse-adapted antibody Fc fragment with a mode of action highly similar to efgartigimod, on vaccine-induced protective immune responses against viral infections. Therefore, mouse vaccination models for COVID-19 and influenza were employed, utilizing an mRNA COVID-19 vaccine (COMIRNATY) and an adjuvanted, inactivated quadrivalent influenza vaccine (Seqirus+AddaVax), respectively. In both models, vaccination induced robust humoral responses. As expected, animals treated with mFc-ABDEG had lower levels of virus-specific IgG, while virus-specific IgM responses remained unaffected. The COVID-19 vaccine induced a strong Th1-type T cell response irrespective of mFc-ABDEG treatment. Influenza vaccination resulted in a poor T cell induction, regardless of mFc-ABDEG treatment, due to the Th2-biased response that inactivated influenza vaccines typically induce. Importantly, mFc-ABDEG treatment had no effect on protective immunity against live viral challenges in both models. Vaccinated animals treated with mFc-ABDEG were equally protected as the non-treated vaccinated controls. These non-clinical data demonstrate that FcRn antagonism with mFc-ABDEG did not affect the generation of vaccine-induced protective humoral and cellular responses, or protection against viral challenges. These data substantiate the clinical observations that, although IgG titers were reduced, FcRn antagonism with efgartigimod did not impair the ability to generate new specific IgG responses, regardless of the timing of vaccination.

01 Jun 2025·LIFE SCIENCES

Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks

Article

Author: Liu, Junyu ; Xu, Xiaofeng ; Yang, Lu ; Li, Min ; Zhou, Yanxia ; Li, Yi ; Peng, Fuhua ; Jiang, Ying ; Zheng, Dong ; Liu, Jia ; Lin, Yanni ; Chen, Xialing

OBJECTIVES:

The purpose of this study was to evaluate the efficacy of Efgartigimod (EFG) in anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis patients during acute attacks.

METHODS:

A case-control study was designed to compare 26 anti-NMDAR encephalitis patients who were treated with EFG, and 15 patients with intravenous immunoglobulin (IVIG), and 23 patients with immunoadsorption with staphylococcal protein A column (SPA-IA) treatment.

RESULTS:

At baseline, no significant differences in mRS scores were observed among the EFG, IVIG, and SPA-IA groups of anti-NMDAR encephalitis patients. When compared with the IVIG group, patients treated with EFG had significantly decreased serum IgG levels. Compared with the SPA-IA group, EFG-treated patients had lower CSF anti-NMDAR antibody titers at admission (p = 0.039) and higher post-treatment IgG levels (p = 0.002). When compared with the IVIG group, SPA-IA patients had higher CASE scores (p = 0.022) and baseline IgG levels (p = 0.023). All groups improved the symptoms of anti-NMDAR encephalitis patients after treatment during acute attacks, with significant decreases in mRS and CASE scores from admission to discharge (p < 0.01). In the EFG and SPA-IA groups, there was a significant reduction in anti-NMDAR antibody titers in both CSF and serum (p < 0.01), while no remarkable decrease was found in the IVIG group. Additionally, serum IgG levels significantly decreased in both the EFG and SPA-IA groups post treatment and during the 1-month follow-up. By the 3-month of follow-up, IgG levels in the blood of both groups remained below the baseline levels.

CONCLUSION:

EFG could be an elegant alternative to both IVIG and SPA-IA therapies for anti-NMDAR encephalitis during acute attacks. It has a better effect on reducing antibody titers than IVIG and is comparable to SPA-IA therapy, and no serious adverse events were observed during infusion.

01 Jun 2025·IMMUNOLOGY LETTERS

Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases

Article

Author: Li, Wei ; Zhang, Jiewen ; Yuan, Lipin ; Liu, Huiqin ; Qin, Jin ; Pang, Rui

OBJECTIVE:

Myasthenia gravis (MG) is an autoimmune disease characterized by disrupted neuromuscular synaptic transmission. Efgartigimod, a human Fc receptor antagonist, has been approved for patients with MG. Its potential use for other IgG-mediated neurological autoimmune diseases is unclear. This study aimed to retrospectively evaluate the efficacy and safety of efgartigimod in patients with neurological autoimmune diseases.

METHODS:

This retrospective study investigated patients with neurological autoimmune diseases who were treated with efgartigimod in the Henan Provincial People's Hospital. The efficacy of the medication was analyzed using the quality-of-life improvement score and the IgG level pre- and post-efgartigimod treatment. The safety of the medication was assessed by considering adverse events and blood parameters. The blood parameters, including routine blood parameters, coagulation, liver, kidney, and immune function.

RESULTS:

Seventeen patients received efgartigimod in the Henan Provincial People's Hospital from September 1, 2023, to January 31, 2024. In MG patients, myasthenia gravis activities of daily living (MG-ADL) reduced after efgartigimod treatment for 4 weeks compared with baseline (P < 0.05). Autoimmune encephalitis (AE) is a group of inflammatory disease with antibodies against neuronal synaptic and cell surface antigens. Similarly, patients with AE had a statistically significant reduction in modified Rankin scale (mRS) after efgartigimod treatment for 4 weeks compared with baseline (P < 0.05). Guillain Barre syndrome (GBS) is an immune-mediated disease of the peripheral nerves and nerve roots. However, the inflammatory neuropathy cause and treatment (INCAT) scale score didn't statistically differ in GBS patients before and after efgartigimod treatment (P > 0.05). The IgG levels significantly reduced after the first infusion and gradually decreased after multiple infusions (P < 0.05). Most subjects did not have increased IgG serum levels before treatment. IgA, IgM, and complement levels didn't differ significantly with efgartigimod treatment (P > 0.05). There were no changes in blood parameters during the treatment (P > 0.05).

CONCLUSIONS:

Efgartigimod was effective and safe in neurological IgG-mediated autoimmune diseases, even in patients without increased IgG serum levels.

293

News (Medical) associated with Efgartigimod Alfa

10 Apr 2025

·www.prnewswire.com

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able to self-inject after proper instruction in subcutaneous injection technique. The single dose prefilled subcutaneous injection was developed as part of argenx's exclusive partnership with Halozyme on their ENHANZE® drug delivery technology, which enables rapid, high-volume delivery of biologics "The FDA approval of VYVGART Hytrulo prefilled syringe represents a significant advancement in treatment options for gMG and CIDP patients, enabling self-administration by patients and potentially further reducing the burden of treatment," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We are delighted that argenx continues to expand use of Halozyme's proven ENHANZE technology to support patient independence and convenience." The approval of VYVGART® Hytrulo prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to VYVGART® Hytrulo in a vial. In addition, human factors validation studies demonstrated that participants with gMG or CIDP, or their caregivers, safely and successfully prepared and administered VYVGART® Hytrulo with the prefilled syringe. Previous FDA approval of VYVGART® Hytrulo for patients with gMG and CIDP was based on the global Phase 3 ADAPT, ADAPT-SC and ADHERE trials. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations by enabling self-administration and broadening the treatment options for the indication referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 3

10 Apr 2025

·endpts.com

J&J, argenx keep rolling out myasthenia gravis data, plus more from #AAN25

Last weekend, researchers gathered in San Diego for the American Academy of Neurology’s annual meeting to discuss the latest advancements and clinical trial data across the neuroscience field. Among the most intensely watched spaces is myasthenia gravis, in which a handful of approvals are soon expected to be challenged by up-and-coming drug programs. UCB and argenx are the primary players currently, along with AstraZeneca/Alexion’s Soliris and Ultomiris franchises. But others may soon join the market, with drugs from J&J, Amgen and Immunovant all in late-stage development. Biohaven also has a program that’s expected to start Phase 1 studies in myasthenia gravis before the end of June, and Cartesian reported data for its cell therapy program earlier this week. Nipocalimab is a major part of J&J’s R&D portfolio. Company executives projected peak sales of at least $5 billion across a potential 10 indications. Myasthenia gravis is first among those efforts, with nipocalimab succeeding in its Phase 3 trial last year. J&J outlined longer-term data for people who participated in that trial, including patients who originally received placebo in the double-blinded portion and then crossed over into taking the drug. After 84 weeks, J&J said nipocalimab resulted in sustained disease control in both groups of patients. The randomized period was 24 weeks, and the open-label follow-up was 60 weeks. Patients who received placebo first and then crossed over had nearly identical mean levels of IgG after the 60-week period, with the levels dropping within the first few weeks. J&J’s executive director of neuroscience Sindhu Ramchandren said because myasthenia gravis is a chronic disease, the data showing nipocalimab’s effectiveness over time helps boost its case overall. “I think of it like diabetes,” she said. “You don’t treat diabetes by just taking insulin for a limited period of time and then hope that it gets cured. In a chronic disease, you need to take your treatments chronically.” J&J submitted its application to the FDA last Aug. 29, and said in January that it received priority review for nipocalimab in myasthenia gravis. Though a PDUFA date has not been disclosed, Wall Street expects a decision by the end of April. Vyvgart has been on the market for a while, first getting approval in December 2021. Argenx is continuing to move forward with other administration routes, getting FDA approval last year for the subcutaneous injection Vyvgart Hytrulo. The subcutaneous version also got FDA approval last year in a rare disease called CIDP (chronic inflammatory demyelinating polyneuropathy), and the company touted long-term data in both disease areas. For the original formulation, 75% of myasthenia gravis patients saw sustained improvement through two and a half years (126 weeks), while 56.5% saw “minimal symptom expression,” according to a press release. Vyvgart Hytrulo, meanwhile, showed long-term benefits in CIDP. Argenx said the drug induced improvements after 36 weeks compared to baseline. The company is continuing to collect real-world data in order to confirm the benefit seen in the pivotal trial. “Stabilization usually has been the target, but now that we have long-term data, there’s an impression people are better off with long-term treatment,” argenx CMO Luc Truyen said. “So that, I think, is important and should be a driver for the field to test.” A third formulation of Vyvgart that uses a self-injector is also under review at the FDA. Regulators are expected to make a decision by the end of April 10. More dispatches:

Clinical ResultPhase 3Drug ApprovalPriority ReviewCell Therapy

10 Apr 2025

·www.biospace.com

Amgen’s Uplizna Deepens Response Through 1 Year in Myasthenia Gravis

iStock, JHVEPhoto Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis. Amgen ’s anti-CD19 antibody Uplizna showed durable and deepening treatment effects for patients with generalized myasthenia gravis, maintaining improved function and disease activity through 1 year of follow-up, according to a data drop on Wednesday. Leerink analysts in a Wednesday note said that responses to Uplizna “progressively improved out to week 52,” adding that its end response is “comparable” to other drugs in the same therapeutic class, such as UCB’s Rystiggo and argenx’s Vyvgart. However, Leerink noted that Uplizna has a more “gradual effectiveness” than its would-be competitors in generalized myasthenia gravis (gMG), a neuromuscular autoimmune condition that causes muscle weakness. In particular, patients on Uplizna “only began to show initial separation from placebo” in terms of activities of daily living after 8 weeks, before reaching statistically significant separation at 26 weeks. “This compares unfavorably vs. Vyvgart,” the analysts wrote, adding that argenx’s asset, significantly distinguishes itself from placebo as early as week 1. Amgen’s data, which were presented at the 2025 Annual Meeting of the American Academy of Neurology and simultaneously published in the New England Journal of Medicine , showed that patients on Uplizna saw significant improvements in activities of daily living compared to those on placebo at 26 weeks. Uplizna also significantly lowered quantitative disease activity over this same time span. In terms of safety, Uplizna was not associated with more frequent serious toxicities than placebo. Common side effects included headache, cough, urinary tract infections and infusion-related reactions. Amgen plans to approval of Uplizna in gMG in the first half of 2025, according to a March 13 press release . Uplizna is an intravenous monoclonal antibody designed to target and bind the CD19 protein, typically found on the surface of mature and immature B cells. The biologic was first approved in 2020 for neuromyelitis optica spectrum disorder, a rare autoimmune condition that affects nerves in the eye and spinal cord. Last week, the FDA signed off on the use of Uplizna for IgG4-related disease, a condition that involves the infiltration of B cells into various organs, causing widespread damage. In this indication, Uplizna has shown the ability to reduce disease-related flares by 87% versus placebo, according to the Phase III MITIGATE trial. Uplizna likewise eliminated the need for glucocorticoids for nearly 90% of patients. Amgen is also proposing Uplizna for gMG, with an approval filing planned for the first half of 2025.

Phase 3Drug ApprovalClinical Result

100 Deals associated with Efgartigimod Alfa

External Link

KEGG	Wiki	ATC	Drug Bank
-	Efgartigimod Alfa	-	DB15270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	Japan	argenx SE	26 Mar 2024
Myasthenia Gravis	United States	arGENX BV	17 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	NDA/BLA	China	Zai Lab (Shanghai) Co., Ltd.	24 Apr 2024
Primary Sjögren's syndrome	Phase 3	United States	argenx SE	04 Dec 2024
Graves Ophthalmopathy	Phase 3	United States	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	China	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Japan	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Austria	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Bulgaria	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	France	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Italy	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Latvia	argenx SE	28 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04188379 (ADVANCE \| ADVANCE IV, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	131	efgartigimod (Efgartigimod)	fsolimjmyp = igtnlkvxqt wzrkazycrb (lvbaebugts, xdlgqdrghy - pzhnybqlwe) View more	-	13 Mar 2025
				Placebo (Placebo)	fsolimjmyp = ycpbvetyfd wzrkazycrb (lvbaebugts, mrfskvgqmq - qnyksqlbsz) View more
NCT04687072 (ADVANCE SC, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	207	Efgartigimod PH20 SC (Efgartigimod PH20 SC)	xnqtnfpaik = zsvgkyvfmz hcxwtiufff (gchvdqoocx, kbustfaopz - azkexobkqm) View more	-	31 Oct 2024
				Placebo PH20 SC (Placebo PH20 SC)	xnqtnfpaik = lqiidnlgjp hcxwtiufff (gchvdqoocx, qlsazbveqn - qbrevssufe) View more
NCT04281472 (ADHERE, CTgov)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	322	Efgartigimod PH20 (Stage A: Efgartigimod PH20 SC)	rypckisvup = kavrbmgcxu yjsqjlaggb (wpohmfzbmo, xhmanuzftn - zdtzdftxbr) View more	-	20 Aug 2024
				Efgartigimod PH20 (Stage B: Efgartigimod PH20 SC)	uvdqspsjbn(clhrcftyrt) = wimjbmkwoq fsfkdjcjyc (jmzvlxzgho, qcgtxoolik - sxoinfnijb) View more
NCT04735432 (ADAPT-SC, NEWS) Manual	Phase 3	Myasthenia Gravis 乙酰胆碱受体（AChR）抗体阳性	-	艾加莫德	tjrmhkaegz(xvoxzfbvdn) = nzikdzkcmm orwskuortq (cnscvcoxcl ) Met	Non-inferior	17 Jul 2024
				efgartigimod IV	tjrmhkaegz(xvoxzfbvdn) = vhjtjyfvxk orwskuortq (cnscvcoxcl ) Met
EAN2024	Not Applicable	-	-	Efgartigimod IV	bofmkxdowr(bdogvvibjx) = jfhsopzvgd jemuwczbjb (vmycxfhlth )	-	28 Jun 2024
				Efgartigimod SC	bofmkxdowr(bdogvvibjx) = dfvzkzefzp jemuwczbjb (vmycxfhlth )
EAN2024	Not Applicable	-	-	Efgartigimod IV	jgledjqkmz(mlasslmtyn) = ddmzabjuhf rogffojrtz (jryfdjeyps, 2.2)	-	28 Jun 2024
EAN2024	Not Applicable	-	-	Efgartigimod	emabsigbuc(xvtdqgbmov) = vlvdpgtevb fyxxaetxzn (jaxxgjtjcs ) View more	-	28 Jun 2024
NCT04281472 (ADHERE, AAN2024)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	322	Efgartigimod PH20 SC 1000mg	kfxmjbxbvk(kjkigciqns) = Most TEAEs were mild to moderate; 3 deaths occurred, none being related to treatment beowwqrihu (xcwqximutd )	Positive	09 Apr 2024
ADAPT/ADAPT+ (AAN2024)	Phase 3	Myasthenia Gravis acetylcholine receptor antibody-positive	-	Efgartigimod	xpvzmnjbmt(hdegpghzwx) = 0.3-point increase suntnjhvhs (rpsvgrqerw ) View more	Positive	09 Apr 2024
				Placebo
P4-14.016 (AAN2024)	Phase 2/3	Autoimmune Diseases IgG-mediated autoimmune disorders	-	Efgartigimod	rdwbieahid(uabffxhlkr) = gltshvqnrx ihaqrpjizb (klplwjiqml )	Positive	09 Apr 2024
				Placebo	rdwbieahid(uabffxhlkr) = vlgfdwfrvn ihaqrpjizb (klplwjiqml )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis